2-(1-piperidinyl)ethyl-4-amino-5-chloro-2-methoxybenzoate | 148868-55-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(1-piperidinyl)ethyl-4-amino-5-chloro-2-methoxybenzoate
• 英文别名: ML 10302；ML-10302；ML10302；M 7319；2-Piperidinoethyl 4-amino-5-chloro-2-methoxybenzoate；2-piperidin-1-ylethyl 4-amino-5-chloro-2-methoxybenzoate
• CAS: 148868-55-7
• 化学式: C₁₅H₂₁ClN₂O₃
• 分子量: 312.796
• InChiKey: RVFIAQAAZUEPPE-UHFFFAOYSA-N

物化性质

• 沸点：
  472.7±45.0 °C(Predicted)
• 密度：
  1.223±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：44 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  64.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : ML 10302
CAS-No. : 148868-55-7
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : 2-Piperidinoethyl 4-amino-5-chloro-2-methoxybenzoate
Formula : C15H21ClN2O3
Molecular Weight : 312,79 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

ML 10302是一种有效的5-HT4受体激动剂，其Ki值为1.07 nM。5-羟色胺(5-HT4)受体激动剂能够通过胆碱能途径刺激肠道运动。ML 10302通过激活胆碱能通路，在小肠和结肠中诱导显著的运动前收缩。此外，ML 10302还具有研究神经病学疾病的应用潜力【1】。

反应信息

• 作为反应物：
  描述：

  4-氯-7-硝基苯并-2-氧杂-1,3-二唑 、 2-(1-piperidinyl)ethyl-4-amino-5-chloro-2-methoxybenzoate 在 potassium iodide 作用下， 以 正丁醇 为溶剂， 反应 12.0h， 以30%的产率得到2-Piperidin-1-ylethyl 5-chloro-2-methoxy-4-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]benzoate
  参考文献：
  名称：

  人类5-HT4受体的第一种荧光拮抗剂的合成和表征。

  摘要：

  基于ML10302 1，有效的5-HT（4）受体激动剂和哌嗪类似物2合成了人类5-HT（4）受体的荧光拮抗剂。这些分子衍生自三个荧光基团：丹磺酰基，萘二甲酰亚胺和NBD（ 7-硝基苯-2-氧杂-1,3-二氮杂-4-基），通过烷基链。合成的分子在结合测定中评估了最近克隆的人5-HT（4（e））受体同工型，在C6神经胶质细胞中稳定表达，[[3] H] GR113808作为放射性配体。亲和力值取决于基础结构以及烷基链长。与基于哌嗪类似物的衍生物相比，基于ML10302的衍生物具有更强的配体。对于基于ML10302的配体，丹磺酰基和NBD衍生物分别通过一个碳原子17a和32的链长连接，导致亲和力接近ML10302。最有效的化合物17a，28和32在具有纳摩尔K（b）值的同一细胞系统中对5-HT刺激的环AMP合成产生抑制作用。更具体地研究了17a，28和32的荧光性质。使用h5-HT（4（e））受体

  DOI：

  10.1021/jm0307887
• 作为产物：
  描述：

  4-氨基-5-氯-2-甲氧基苯甲酸 在 potassium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 2-(1-piperidinyl)ethyl-4-amino-5-chloro-2-methoxybenzoate
  参考文献：
  名称：

  4-氨基-5-氯-2-甲氧基苯甲酸的新酯作为有效的激动剂和5-HT4受体拮抗剂。

  摘要：

  合成了许多衍生自4-氨基-5-氯-2-甲氧基苯甲酸和取代的1-哌啶乙醇的苯甲酸酯，它们在豚鼠回肠的电刺激的肠神经丛和纵肌中是有效的5-HT4受体激动剂。和大鼠食道肌肉。哌啶环被Me，OH，NH-Ac或CONH2基团单取代后，化合物等效于7a（ML 10302），这是先前报道的具有纳摩尔摩尔亲和力的5-HT4受体激动剂。7a，k与5-羟色胺（5-HT）一样有效，但最大响应仅为5-HT的60-80％，表明这些化合物具有部分激动剂特性。在大鼠纹状体中用[3H] GR 113808进行结合测定，发现其中一些化合物对5-HT4受体具有纳摩尔摩尔亲和力（7a，Ki = 1.07 +/- 0.5 nM； 7k，Ki = 1。0 +/- 0.3 nM）。在哌啶环上引入两个甲基导致2-[（（顺式和反式-3,5-二甲基哌啶基）乙基] -4-氨基-5-氯-2-甲氧基苯甲酸酯）的药理学特性发生了显着变化， 7克，小时

  DOI：

  10.1021/jm960320m

文献信息

• Preparation andIn Vitro Pharmacology of 5-HT4 Receptor Ligands. Partial Agonism and Antagonism of Metoclopramide Analogous Benzoic Esters
  作者：Sigurd Elz、Andreas Keller

  DOI：10.1002/ardp.19953280705

  日期：——

  functional in vitro assays with regard to affinity for serotoninergic 5‐HT4, 5‐HT3 and muscarinic M3 receptors. The affinities for 5‐HT4 and M3 receptors were below 6.0 (pKB or pA2). On 5‐HT4 receptors in guinea‐pig ileal longitudinal muscle and rat oesophagus, the majority of compounds revealed partial 5‐HT4 receptor agonism susceptible to blockade by SDZ 205557, a reference 5‐HT4 receptor antagonist

  胃促动力苯甲酰胺甲氧氯普胺 (1) 的脂环酯类似物及其酯同源物 SDZ 205557 (2)，一种 5-HT4 受体拮抗剂，通过 4-氨基-5-氯-2-甲氧基苯甲酸酯与 N-( 2-氯乙基）取代的脂环胺。化合物13b的溴和碘类似物（2-（1-哌啶基）乙基4-氨基-5-氯-2-甲氧基苯甲酸酯）通过脱氯-13b与N-卤代琥珀酰亚胺的卤化得到。在功能性体外试验中评估了该系列对 5-羟色胺能 5-HT4、5-HT3 和毒蕈碱 M3 受体的亲和力。5-HT4 和 M3 受体的亲和力低于 6.0（pKB 或 pA2）。在豚鼠回肠纵肌和大鼠食管中的 5-HT4 受体上，大多数化合物显示出部分 5-HT4 受体激动作用，容易被 SDZ 205557 阻断，参考 5-HT4 受体拮抗剂（pKb = 7.25 - 7.73（豚鼠回肠）和 7.09 - 7.43（大鼠食道））。相对激动剂效力在 5-303% (5-HT:
• Medicament
  申请人：——

  公开号：US20020173505A1

  公开（公告）日：2002-11-21

  A compound having agonist activity to the 5-HT 4 receptor for use as a medicament and the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment of disorders involving bronchocontraction of a human or animal body is described, as well as methods of treatment, wherein said compounds are administered. Further, a compound having antagonist activity to the 5-HT 2 a receptor for use as a medicament and the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment or disorders involving bronchocontraction of a human or animal body is described, as well as methods of treatment, wherein said compounds are administered. Moreover, a composition comprising a combination of compounds comprising at least one compound with agonist activity to the 5-HT 4 receptor agonist and at least one compound with antagonist activity to the 5-HT 2 , receptor antagonist is described, as well as such a composition for use as a medicament, the use of said composition for the manufacture of a medicament for therapeutic or prophylactic treatment of disorders involving broncocontraction of a human or animal body, and methods of treatment, wherein said compositions are administered.

  一种对 5-HT 4 描述了一种可用作药物的化合物，以及在制造用于治疗或预防涉及人体或动物支气管收缩紊乱的药物时使用所述化合物的情况，还描述了施用所述化合物的治疗方法。此外，还描述了一种对 5-HT 2 受体的拮抗剂活性的化合物，以及治疗方法，其中所述化合物被施用。此外，还介绍了一种包含化合物组合的组合物，该组合物包含至少一种对 5-HT 4 受体激动剂活性的至少一种化合物和对 5-HT 2 Ⅳ受体拮抗剂的化合物的组合，以及这种组合物作为药物的用途，所述组合物用于制造治疗或预防性治疗涉及人体或动物支气管收缩紊乱的药物的用途，以及施用所述组合物的治疗方法。
• Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity
  申请人：Compan Valerie

  公开号：US20060116341A1

  公开（公告）日：2006-06-01

  This invention relates to the use of a ligand of the 5-HT 4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT 4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invention also relates to a method for identifying a compound that is biologically active in the treatment and/or the prevention of a pathology associated with an obsessional conduct or obesity including: a) placing the 5-HT 4 receptor or a functionally equivalent receptor in contact with this biologically active compound, and b) the determination of whether this biologically active compound is capable of modulating the basal activity of the 5-HT 4 receptor or of a functionally equivalent receptor.

  本发明涉及一种 5-HT 4 受体的配体或该配体的药学上可接受的盐，以及编码 5-HT 4 受体或功能等效受体的核酸，用于治疗和/或预防与强迫行为有关的病理，如厌食症、贪食症和滥用药物成瘾或肥胖症。本发明还涉及一种鉴定化合物的方法，该化合物在治疗和/或预防与强迫行为或肥胖症相关的病理方面具有生物活性，包括：a) 将 5-HT 4 受体或功能相当的受体与这种生物活性化合物接触，以及 b) 确定这种生物活性化合物是否能够调节 5-HT 4 受体或功能相当的受体的基础活性。
• COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION
  申请人：Respiratorius AB

  公开号：EP1173168A2

  公开（公告）日：2002-01-23
• RECEPTOR AGONISTS AND ANTAGONISTS
  申请人：Respiratorius AB

  公开号：EP1185263A2

  公开（公告）日：2002-03-13